The Cancer Biomarkers Market is predicted to reach US$ 12.2 billion$ by 2030 from US$ 12.2 billion in 2021, and to grow at a CAGR of ~11.2% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
Type (Genomic Biomarkers, Proteomic Biomarkers and Transcriptomic Biomarkers), Profiling Technology (Omic Technologies, Imaging Technologies and Immunoassays), Application (Diagnostics, Drug Discovery & Development, and Personalized Medicine), Cancer Type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Blood Cancer and Skin Cancer)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Qiagen NV, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., General Electric Company, Abbott Laboratories Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., bioMérieux SA, and Myriad Genetics, Inc., among others.
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2031
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Cancer Biomarkers - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Cancer Biomarkers - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Cancer Biomarkers - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Cancer Biomarkers - ANALYSIS & FORECAST, BY REGION
North America Cancer Biomarkers
1. North America Cancer Biomarkers , by Country
1. US
2. Canada
1. North America Cancer Biomarkers , by Product
2. North America Cancer Biomarkers , by Type
3. North America Cancer Biomarkers , by Gender
4. North America Cancer Biomarkers , by Sales Channel
3. Europe Cancer Biomarkers
1. Europe Cancer Biomarkers , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Cancer Biomarkers , by Product
3. Europe Cancer Biomarkers , by Type
4. Europe Cancer Biomarkers , by Gender
5. Europe Cancer Biomarkers , by Sales Channel
4. Asia Pacific Cancer Biomarkers
1. Asia Pacific Cancer Biomarkers , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Cancer Biomarkers , by product
3. Asia Pacific Cancer Biomarkers , by Type
4. Asia Pacific Cancer Biomarkers , by Gender
5. Asia Pacific Cancer Biomarkers , by Sales Channel
5. Rest of the World Cancer Biomarkers
1. Rest of the World Cancer Biomarkers , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Cancer Biomarkers , by Product
3. Rest of the World Cancer Biomarkers , by Type
4. Rest of the World Cancer Biomarkers , by Gender
5. Rest of the World Cancer Biomarkers , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 48